[Molecular pathogenesis and management of myeloma bone disease]

Area of Science:

• Oncology
• Orthopedics
• Hematology

Background:

• Multiple myeloma (MM) significantly impacts bone health, causing destructive lesions that reduce patient quality of life.
• MM bone lesions arise from dysregulated bone remodeling, involving inhibited osteoblast differentiation and activated osteoclasts within the bone marrow microenvironment.
• Osteocytes, the most abundant bone cells, play a crucial role in the pathogenesis of MM bone disease.

Purpose of the Study:

• To review the molecular pathology of multiple myeloma bone lesions.
• To discuss current and emerging management strategies for MM bone lesions.
• To highlight the importance of addressing bone complications in MM patient care.

Main Methods:

• Literature review of molecular mechanisms underlying MM bone lesions.
• Analysis of imaging modalities for MM bone lesion diagnosis (e.g., low-dose CT, MRI, PET/CT).
• Synthesis of information on therapeutic advances and management approaches for MM bone disease.

Main Results:

• Novel anti-MM agents have improved survival, yet bone lesions persist as a significant clinical challenge.
• Understanding the role of the bone marrow microenvironment and osteocytes is key to MM bone pathology.
• Advanced imaging techniques are vital for accurate diagnosis and monitoring of MM bone lesions.

Conclusions:

• Effective management of MM bone lesions is critical for improving patient quality of life and overall prognosis.
• Continued research into the molecular pathology of MM bone disease will drive the development of targeted therapies.
• A multidisciplinary approach integrating novel anti-MM therapies with bone-targeted treatments is essential for optimal patient outcomes.